Ka Hou Christien Li1,2,3, Mengqi Gong4, Guangping Li4, Adrian Baranchuk5, Tong Liu4, Martin C S Wong6, Aaron Jesuthasan3, Rachel W C Lai1,2, Jenny Chi Ling Lai1,2, Alex Pui Wai Lee1,2, Antoni Bayés-Genis7,8, Rafael de la Espriella9,10,11, Juan Sanchis9,10,11, William K K Wu2,12,13, Gary Tse1,2,13, Julio Nuñez9,10. 1. Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. 2. Faculty of Medicine, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China. 3. Faculty of Medicine, Newcastle University, England, UK. 4. Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, china. 5. Department of Medicine, Kingston General Hospital, Queen's University, Kingston, Ontario, Canada. 6. JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. 7. Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 8. Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. 9. Cardiology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain. 10. Departamento de Medicina, Universitat de València, Valencia, Spain. 11. CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain. 12. Department of Anaesthesia and Intensive Care, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. 13. Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China.
Abstract
BACKGROUND: Carbohydrate antigen-125 (CA125) is an ovarian cancer marker, but recent work has examined its role in risk stratification in heart failure. A recent meta-analysis examined its prognostic value in heart failure generally. However, there has been no systematic evaluation of its role specifically in acute heart failure (AHF). METHODS: PubMed and EMBASE databases were searched until 11 May 2018 for studies that evaluated the prognostic value of CA125 in AHF. RESULTS: A total of 129 and 179 entries were retrieved from PubMed and EMBASE. Sixteen studies (15 cohort studies, 1 randomised trial) including 8401 subjects with AHF (mean age 71 years old, 52% male, mean follow-up 13 months, range of patients 525.1±598.2) were included. High CA125 levels were associated with a 68% increase in all-cause mortality (8 studies, HRs: 1.68, 95% CI 1.36 to 2.07; p<0.0001; I2: 74%) and 77% increase in heart failure-related readmissions (5 studies, HRs: 1.77, 95% CI 1.22 to 2.59; p<0.01; I2: 73%). CA125 levels were higher in patients with fluid overload symptoms and signs compared with those without them, with a mean difference of 54.8 U/mL (5 studies, SE: 13.2 U/mL; p<0.0001; I2: 78%). CONCLUSION: Our meta-analysis found that high CA125 levels are associated with AHF symptoms, heart failure-related hospital readmissions and all-cause mortality. Therefore, CA125 emerges as a useful risk stratification tool for identifying high-risk patients with more severe fluid overload, as well as for monitoring following an AHF episode.
BACKGROUND: Carbohydrate antigen-125 (CA125) is an ovarian cancer marker, but recent work has examined its role in risk stratification in heart failure. A recent meta-analysis examined its prognostic value in heart failure generally. However, there has been no systematic evaluation of its role specifically in acute heart failure (AHF). METHODS: PubMed and EMBASE databases were searched until 11 May 2018 for studies that evaluated the prognostic value of CA125 in AHF. RESULTS: A total of 129 and 179 entries were retrieved from PubMed and EMBASE. Sixteen studies (15 cohort studies, 1 randomised trial) including 8401 subjects with AHF (mean age 71 years old, 52% male, mean follow-up 13 months, range of patients 525.1±598.2) were included. High CA125 levels were associated with a 68% increase in all-cause mortality (8 studies, HRs: 1.68, 95% CI 1.36 to 2.07; p<0.0001; I2: 74%) and 77% increase in heart failure-related readmissions (5 studies, HRs: 1.77, 95% CI 1.22 to 2.59; p<0.01; I2: 73%). CA125 levels were higher in patients with fluid overload symptoms and signs compared with those without them, with a mean difference of 54.8 U/mL (5 studies, SE: 13.2 U/mL; p<0.0001; I2: 78%). CONCLUSION: Our meta-analysis found that high CA125 levels are associated with AHF symptoms, heart failure-related hospital readmissions and all-cause mortality. Therefore, CA125 emerges as a useful risk stratification tool for identifying high-risk patients with more severe fluid overload, as well as for monitoring following an AHF episode.
Authors: Jay Ritzema; Richard Troughton; Iain Melton; Ian Crozier; Robert Doughty; Henry Krum; Anthony Walton; Philip Adamson; Saibal Kar; Prediman K Shah; Mark Richards; Neal L Eigler; James S Whiting; Garrie J Haas; J Thomas Heywood; Christopher M Frampton; William T Abraham Journal: Circulation Date: 2010-02-22 Impact factor: 29.690
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Nikos T Kouris; Dimitra D Kontogianni; Eftihia P Papoulia; Georgia S Goranitou; Ioannis D Zaharos; Haris A Grassos; Eleni M Kalkandi; Maria D Sifaki; Dimitris K Babalis Journal: Hellenic J Cardiol Date: 2006 Sep-Oct
Authors: Julio Núñez; Gabriel A Rabinovich; Justo Sandino; Luis Mainar; Patricia Palau; Enrique Santas; Maria Pilar Villanueva; Eduardo Núñez; Vicent Bodí; Francisco J Chorro; Gema Miñana; Juan Sanchis Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240
Authors: Christina Ip; King Sum Luk; Vincent Lok Cheung Yuen; Lorraine Chiang; Ching Ki Chan; Kevin Ho; Mengqi Gong; Teddy Tai Loy Lee; Keith Sai Kit Leung; Leonardo Roever; George Bazoukis; Konstantinos Lampropoulos; Ka Hou Christien Li; Gary Tse; Tong Liu Journal: Int J Cardiol Heart Vasc Date: 2021-10-18
Authors: Patrícia Lourenço; Filipe M Cunha; Catarina Elias; Catarina Fernandes; Isaac Barroso; João T Guimarães; Paulo Bettencourt Journal: ESC Heart Fail Date: 2022-01-05
Authors: Agata Zdanowicz; Szymon Urban; Barbara Ponikowska; Gracjan Iwanek; Robert Zymliński; Piotr Ponikowski; Jan Biegus Journal: J Pers Med Date: 2022-05-29
Authors: Weronika Bulska-Będkowska; Elżbieta Chełmecka; Aleksander J Owczarek; Katarzyna Mizia-Stec; Andrzej Witek; Aleksandra Szybalska; Tomasz Grodzicki; Magdalena Olszanecka-Glinianowicz; Jerzy Chudek Journal: J Clin Med Date: 2019-05-03 Impact factor: 4.241
Authors: C Shi; H H van der Wal; H H W Silljé; M M Dokter; F van den Berg; L Huizinga; M Vriesema; J Post; S D Anker; J G Cleland; L L Ng; N J Samani; K Dickstein; F Zannad; C C Lang; P L van Haelst; J A Gietema; M Metra; P Ameri; M Canepa; D J van Veldhuisen; A A Voors; R A de Boer Journal: J Intern Med Date: 2020-05-05 Impact factor: 8.989
Authors: Mar Domingo; Josep Lupón; Nicolas Girerd; Laura Conangla; Marta de Antonio; Pedro Moliner; Evelyn Santiago-Vacas; Pau Codina; German Cediel; Giosafat Spitaleri; Beatriz González; Violeta Diaz; Carmen Rivas; Patricia Velayos; Julio Núñez; Antoni Bayes-Genís Journal: ESC Heart Fail Date: 2021-11-01
Authors: Marko Kumric; Tina Ticinovic Kurir; Josko Bozic; Duska Glavas; Tina Saric; Bjørnar Marcelius; Domenico D'Amario; Josip A Borovac Journal: Card Fail Rev Date: 2021-06-12